Patients presenting with lesions with shiny white streaks on dermoscopy should undergo biopsy for possible melanoma.
Melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.
An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.
Individuals categorized as overweight or obese had a significantly increased risk for malignant melanoma.
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination TherapyOctober 20, 2017
[OncoTargets and Therapy] This article examines a case of metastatic melanoma in which the patient had an excellent response to apatinib/TMZ combination therapy with progression-free survival for more than one year.
Median overall survival from time of diagnosis has increased from 7.5 to 22.7 months in the last decade.
Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.
A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.
Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care ProvidersAugust 11, 2017
Awareness of personal genetic risk for melanoma may prompt patients to discuss cancer risk with family and health care professionals, and make lifestyle changes.
The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.
When researchers sent sample slides to pathologists for review, the assessments varied widely and some pathologists even disagreed with their own initial assessment when retested months later.
Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.
Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.
'Conquer Fear' decreased fear among survivors of breast and colorectal cancer and melanoma compared with relaxation techniques.
Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.
Two-gene pigmented lesion test classifies skin lesions as melanoma or nonmelanoma, helping with diagnostic challenges faced with the visual image and pattern recognition approach.
Dermatologist assessment of screening practices addresses the lack of a national consensus on screening guidelines for melanoma.
Patients with psoriasis had 1.53 times greater risk of developing a malignancy, regardless of the type of psoriasis therapy they are receiving.
Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.
Despite their efficacy in metastatic melanoma, KIs include risk of serious side effects in patients. This overview explains the effects and management recommendations for 4 agents used to treat metastatic melanoma.
Rechallenge with dabrafenib plus trametinib demonstrated antitumor activity in patients who had previously progressed on BRAF inhibitor therapy.
Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.
Researchers sought to conduct a cost-effectiveness analysis of immunotherapy for patients with advanced melanoma.
Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.
Using statistical models, predictions were made for death rates from melanoma in 3 three countries and based on availability of a treatment.
Researchers compared the ability of an artificial-intelligence algorithm to recognize and classify skin cancers with the clinical evaluations of dermatologists.
Induction therapy with intravenous interferon α-2b appeared to be no better than observation alone for the management of patients with intermediate-risk melanoma.
Results of a series of Internet surveys revealed customers' perceptions of harms, benefits, and limitations of genetic information received from direct-to-consumer genetic testing.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|